Edition:
United Kingdom

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

2.42USD
17 Aug 2018
Change (% chg)

$-0.07 (-2.81%)
Prev Close
$2.49
Open
$2.45
Day's High
$2.46
Day's Low
$2.42
Volume
2,068
Avg. Vol
30,643
52-wk High
$3.70
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Soleno Therapeutics Receives Fast Track Designation From FDA For DCCR
Monday, 30 Jul 2018 

July 30 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM FDA FOR DCCR FOR TREATMENT OF PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Q1 Loss Per Share $0.19
Wednesday, 16 May 2018 

May 16 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17 FROM CONTINUING OPERATIONS.Q1 LOSS PER SHARE $0.19.  Full Article

Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Soleno Therapeutics Inc ::JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING.  Full Article

Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Soleno Therapeutics Inc ::BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING.  Full Article

Soleno Therapeutics Announces $15 Million Private Placement
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT.SOLENO THERAPEUTICS INC - SOLENO TO SELL 8.1 MILLION OF ITS COMMON SHARES AT $1.8425/SHARE.SOLENO THERAPEUTICS - TO USE PROCEEDS CONDUCT PLANNED PHASE III PROGRAM OF DIAZOXIDE CHOLINE CONTROLLED-RELEASE IN PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, OAHL WILL INVEST UP TO $2.2 MILLION IN TRANCHES TO PURCHASE SHARES OF OUR CAPNIA SUBSIDIARY.SOLENO THERAPEUTICS INC - CAPNIA WILL NO LONGER BE A WHOLLY-OWNED SUBSIDIARY OF SOLENO.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, GOING FORWARD, OAHL WILL BE RESPONSIBLE FOR FUNDING OPERATIONS OF CAPNIA.  Full Article

Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.24 from continuing operations.Q3 loss per share $0.35.  Full Article

BRIEF-Soleno Therapeutics Reports Q4 Loss Per Share $0.43

* Q4 LOSS PER SHARE $0.39 FROM CONTINUING OPERATIONS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)